Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.50 |
| ▸ | CNR1 | P21554 | 3/20 | 0.50 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5221653 | 0.86 | HPGD (0.56) | CCR1HPGDSMN1; SMN2ALDH1A1TYK2 | |
| Hydrochloric Acid SCHEMBL4682469 | 0.79 | HPGD (0.47) | CCR1HPGDSMN1; SMN2ALDH1A1TYK2 | |
| SCHEMBL13163165 | 0.79 | HPGD (0.50) | HPGDSMN1; SMN2ALDH1A1TYK2THRB | |
| SCHEMBL4681864 | 0.79 | CA2 (0.54) | CNR2CNR1CCR1HPGDSMN1; SMN2 | |
| SCHEMBL12031902 | 0.77 | CCR1 (0.67) | CCR1HPGDSMN1; SMN2ALDH1A1L3MBTL1 | |
| SCHEMBL13634677 | 0.75 | THRB (0.48) | CCR1HPGDSMN1; SMN2ALDH1A1THRB | |
| SCHEMBL13634478 | 0.75 | THRB (0.48) | CCR1HPGDSMN1; SMN2ALDH1A1TYK2 | |
| SCHEMBL24571390 | 0.75 | HPGD (0.53) | HPGDSMN1; SMN2ALDH1A1TYK2THRB | |
| SCHEMBL15271735 | 0.75 | GLA (0.55) | HPGDSMN1; SMN2ALDH1A1TYK2THRB | |
| SCHEMBL24567577 | 0.75 | HPGD (0.53) | HPGDSMN1; SMN2ALDH1A1TYK2THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1392655-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2008-07-16 | — | — | EP | disclosed |
| EP-1198456-B1 | POTASSIUM CHANNEL OPENERS | ABBOTT LAB (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1392655-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2004-03-03 | — | — | EP | disclosed |
| US-6645968-B2 | E.g., N-(1-((anilinocarbonyl)amino)-2,2,2-trichloroethyl)-4-methyl-benzamide; antiepileptic, -ischemic and cardiotonic agents; sexual, eating and urogenital disorders; asthma; migraines; | ABBOTT LABORATORIES | 2003-11-11 | — | — | US | disclosed |
| WO-2002062762-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2002-08-15 | — | — | WO | disclosed |
| EP-1198456-A2 | POTASSIUM CHANNEL OPENERS | Abbott Laboratories (US) | 2002-04-24 | — | — | EP | disclosed |
| US-20020028836-A1 | Potassium channel openers | ABBVIE INC. | 2002-03-07 | — | — | US | disclosed |
| WO-2001009096-A2 | POTASSIUM CHANNEL OPENERS | ABBOTT LABORATORIES (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020028836-A1 | Potassium channel openers | KCNJ2, KCNJ11, KCNJ1 | CNR2 2077/4885CNR1 1068/4885CCR1 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.